From 1 July 2026, the Tasmanian Government is funding a free infant meningococcal B (MenB) vaccine program.

Under the program, meningoccocal B vaccination will be available at 6 weeks, 4 months and 12 months of age, with a catch-up program offered to children born before 1 July 2025 and aged less than 2 years. 

People with invasive meningococcal disease (IMD) can become extremely unwell very quickly. IMD is rare, but it can be life-threatening and can cause long-term complications. There are five vaccine-preventable subtypes of meningococcal disease: A, C, W, Y and B.

Meningococcal ACWY vaccination is provided on the NIP for babies, teens and people with certain medical conditions. Meningococcal B vaccination is offer on the NIP for high-risk groups including First Nations children and people with certain medical conditions, and to other groups through jurisdiction-based programs.

MVEC strongly recommends everyone wishing to be protected against ACWY and B strains of meningococcal disease be immunised. Those aged 6 weeks of age and older who do not meet the funding criteria can purchase vaccines privately through some councils, GPs and pharmacies. 

For more information about Tasmania’s meningococcal B vaccination program, visit: Tasmanian Department of Health: Infant meningococcal B (MenB) vaccine program.

To read more about meningococcal disease, transmission, epidemiology and prevention, got to MVEC:脑膜炎球菌.

MVEC acknowledges the traditional owners of the lands on which we live, work and educate. We pay our respects to their Elders, past, present and emerging.
We are committed to honouring Australian Aboriginal and Torres Strait Islander peoples’ unique cultural and spiritual relationships to the land, waters and seas.

关于 MVEC

墨尔本疫苗教育中心 (MVEC) 是一个教育网站,旨在为医疗保健专业人员和公众提供最新的免疫接种信息。我们位于研究机构默多克儿童研究所 (MCRI),隶属于维多利亚疫苗安全服务机构 SAEFVIC(社区接种疫苗后的不良事件监测)。

分享这个